Mark David Orland, Aashray Mandala, Serhan Unlu, Felipe de Almeida Sartori, Nandini Rajaram Siva, Asfand Yar Cheema, Carmelo Gurnari, Atsushi Marumo, Zachary Brady, Valeria Visconte, Jaroslaw P. Maciejewski
5 min
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for managing type 2 diabetes and obesity. Beyond metabolic regulation, these drugs possess pleiotropic properties, including potential immunomodulatory effects. This study investigated whether initiating GLP-1RA therapy after a cancer diagnosis influences the progression of stage I-III solid tumors to metastatic (stage IV) disease. Using the TriNetX Global Health Research Network, researchers identified 10,225 patients across seven cancer types—breast, prostate, non-small cell lung cancer (NSCLC), colorectal (CRC), hepatocellular (HCC), renal cell (RCC), and pancreatic adenocarcinoma. Patients receiving GLP-1RAs were propensity-matched 1:1 with patients receiving DPP-4 inhibitors, controlling for variables such as BMI, glycemic factors, comorbidities, and oncologic treatments.
The analysis revealed that GLP-1RA exposure was associated with a reduced risk of metastatic progression in six out of the seven malignancies studied. This reduction reached statistical significance in four specific cancer types: NSCLC, breast cancer, CRC, and HCC. Furthermore, the researchers analyzed data from The Cancer Genome Atlas (TCGA) to determine if the expression of the GLP-1 receptor (GLP-1R) within tumors correlated with patient outcomes. They found that high tumor GLP-1R expression was independently associated with improved overall survival across all seven tumor types, with the strongest association observed in breast cancer.
These findings suggest that GLP-1RAs may offer an unexpected clinical benefit in oncology by potentially slowing cancer progression. Given the high prevalence of diabetes and obesity among cancer patients, identifying existing medications that might also exert antineoplastic effects is of significant clinical interest. While the results are promising, the authors emphasize that these observational findings must be confirmed through prospective randomized controlled trials to establish causality and to better understand the underlying biological mechanisms by which GLP-1RAs might inhibit tumor progression.
Sam: That's the structure. The proposed pathways include immunomodulation and direct receptor-mediated signaling, though the paper doesn't resolve which is dominant. The TCGA correlation is supportive, not mechanistically definitive.
Alex: Where would a careful referee push back?
Sam: The primary vulnerability is that this is retrospective observational data. Propensity score matching reduces confounding but doesn't eliminate it, and the residual confounders here are particularly tricky. Duration of therapy and the timing of initiation relative to the cancer's natural history are difficult to pin down in administrative data. You're always at risk of temporal confounding—patients who are already doing better may be more likely to be started on, or maintained on, these drugs, which would inflate the apparent benefit.
Alex: The immortal time problem, essentially.
Sam: That's the core concern. What you're seeing is an association. Directionality and causality are not established by this design. That's not a dismissal of the findings—it's a precise statement of what the evidence can and cannot support at this stage.
Alex: So for a clinician managing early-stage breast cancer, this doesn't change practice yet.
Sam: Not yet. The appropriate read is hypothesis-generating. The findings justify a prospective trial designed specifically to test GLP-1 agonists in an oncologic context, with pre-specified endpoints and randomization. That's what the data is pointing toward.
Alex: What strikes me is the conceptual shift, even if the evidence is preliminary. We've spent years thinking about this drug class in terms of pancreatic beta cells and adipose tissue. The idea that the receptor might be expressed on solid tumors and functionally relevant to their progression is a genuinely different framing.
Sam: And that's what makes this worth paying attention to, even now. If prospective data confirms it, we're not just talking about a metabolic adjunct for diabetic cancer patients—we're talking about a drug class that may actively modify oncologic trajectory. That would require rethinking how these agents are positioned in cancer care. The evidence isn't there yet, but the question is now well-formed enough to be worth testing rigorously.
Alex: Thanks for walking through that. And thanks to everyone listening to ResearchPod.